Defining Personalized Care Plans in Metastatic Castration-Resistant Prostate Cancer

STATEMENT OF NEED

Prostate cancer is the most common tumor type among men in the United States. Typically, androgen deprivation therapy is administered for progressive disease. However, castration resistance or unresponsiveness to androgen deprivation therapy or to antiandrogens frequently develops over time. The transition from castration-sensitive to castration-resistant disease has yet to be understood and represents a significant unmet need. Metastatic CRPC is the primary cause of prostate-related mortality, accounting for an estimated 26,730 deaths annually. Median overall survival remains less than 2 years.

TARGET AUDIENCE

Medical oncologists, urologists, oncology advanced practitioners, oncology and urology nurses, and other health care professionals involved in the treatment of patients with castration-resistant prostate cancer.

LEARNING OBJECTIVES

Upon completion of this activity, participants should be able to:

Assess predictive and prognostic markers to refine personalized care plans for patients with metastatic CRPC
Evaluate sequential treatment strategies and combination therapies for patients with metastatic CRPC
Apply emerging data on novel therapeutic regimens in treatment selection for patients with metastatic CRPC